

Two Clinical Trials Completed With Unprecedented Results

- Results achieved on late-stage breast cancer patients who had already failed **all other options**
- Rapid regressions seen, as soon as **6 weeks from treatment**
- Median lifespan in recent trial was **5x longer than expected**
- Flagship case (below) saw regressions in breast, lung, and uniquely, even the **brain**

Aggressively Advancing into Next FDA Clinical Trial


- Upcoming clinical trial to launch within 6 months
- To include up to 24 late-stage breast cancer patients
- Substantial research program in parallel to determine how applicable BriaVax might be to **other cancers types as well**

Valuation & Structure

- Recent IPO onto TSX Venture under ticker **BCT**
- Clean structure with no debt, and enough cash to fund upcoming clinical trial
- IPO at entry-level valuation of \$15mm, the bare cost to conduct work done to date
- **Growth potential ahead**


BriaCell’s vaccine, BriaVax, has shown proof of principle in its small Phase-I Pilot Study; its findings are unique; to the best of our knowledge **there are no published results comparable from any other similar clinical trials**

Baseline – Before Treatment




MRI shows malignant breast cancer tumor of 15.1mL volume

3 Vaccines – 6 Weeks Treatment



Within 6 weeks there was marked response and regression seen

6 Vaccines – 20 Weeks Treatment



Less than 5 months from start, tumor regressed by 90% to 1.6mL

